Table S1. Comparison of symptom severity among solid organ transplant recipients who completed a SARS-CoV-2 vaccine series.

Dosage	Dose 1			Dose 2			
Symptom Severity	***Mild[1]***	***Moderate[2]***	***Severe[3]***	***Mild[1]***	***Moderate[2]***	***Severe[3]***	**P-value**
Any local site symptom, %		85			78		<0.001
Pain, %	62	20	2	60	16	1	<0.001
Swelling, %	13	1	<1	12	1	0	0.4
Redness, %	8	1	<1	10	1	0	0.2
Any systemic adverse symptom %		49			69		<0.001
Fatigue, %	22	12	2	34	19	3	<0.001
Headache, %	21	6	1	30	10	2	<0.001
Myalgias, %	11	3	1	18	5	1	<0.001
Chills, %	6	1	1	14	3	1	<0.001
Fever, %	3	1	<1	9	3	<1	<0.001
Diarrhea, %	4	1	<1	9	1	<1	<0.01
Vomiting, %	1	1	<1	1	1	<1	0.8

[1]Mild: does not interfere with activity.

[2]Moderate: some interference with activity.

[3]Severe: prevents daily activity.

Table S2. Association between local and systemic symptoms and development of detectable antibody response after dose 1 of a SARS-CoV-2 mRNA vaccine.

	Detectable antibody response after dose 1	
	aIRR	**P-value**
Moderate to severe local symptoms		
Pain	$_{1.11}1.66_{2.47}$	0.01
Swelling	$_{0.39}1.09_{3.07}$	0.9
Redness	$_{1.83}3.92_{8.41}$	<0.01
Moderate to severe systemic symptoms		
Fatigue	$_{0.65}1.19_{2.18}$	0.6
Headache	$_{0.54}1.13_{2.36}$	0.7
Myalgias	$_{0.51}1.11_{2.42}$	0.8
Chills	$_{0.86}2.11_{5.17}$	0.1
Fever	$_{0.09}0.74_{6.28}$	0.8
Diarrhea or vomiting	$_{0.04}0.34_{2.60}$	0.3

N = 557 participants with antibody data after dose 1

Abbreviations: aIRR, adjusted incidence rate ratio; mTOR, mammalian target of rapamycin; Ref, reference